Drug Discovery

CN Bio, University of Melbourne collaborate to advance therapies for respiratory complications in recovered Covid-19 patients

CN Bio announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients.

Eli Lilly to buy gene therapy firm Prevail Therapeutics for $1.04bn

Eli Lilly has agreed to acquire US-based gene therapy company Prevail Therapeutics for an aggregate value of up to $1.04bn.

Eureka Therapeutics announces preclinical results of InvisiMask human antibody nasal spray against SARS-CoV-2 infection

Eureka Therapeutics announced successful preclinical results from its InvisiMask Human Antibody Nasal Spray in mice, which offers protection against SARS-CoV-2 S pseudotyped virus infection for up to 10 hours.

EQT IX offers to buy Swedish firm Recipharm for $2.1bn

Private investment organisation EQT IX has offered to acquire Swedish contract development and manufacturing organisation (CDMO) Recipharm for $2.1bn.

AstraZeneca to buy Alexion Pharmaceuticals for $39bn

AstraZeneca has agreed to acquire US-based biopharmaceutical company Alexion Pharmaceuticals in a deal valued at $39bn.

Gilead Sciences to acquire MYR

Gilead Sciences and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash.

Boehringer to acquire Swiss biotech company NBE-Therapeutics for €1.18bn

Boehringer Ingelheim has agreed to acquire clinical-stage Swiss biotechnology company NBE-Therapeutics for €1.18bn for enhancing its cancer pipeline portfolio.

CYBIN signs agreement to acquire Adelia Therapeutics

Cybin, a life sciences company focused on psychedelic pharmaceutical therapies, today announced the signing of a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. (“Adelia”) for up to CDN$20,161,575 (approximately $15.75m) in an all-stock transaction (the “Transaction”).

Syros acquires clinical-stage drug candidate for acute promyelocytic leukemia

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, today announced that it has acquired from Orsenix, LLC (Orsenix) all of its assets related to SY-2101, formerly known as ORH-2014, a novel oral form of arsenic trioxide (ATO).